Sanofi has successfully acquired Blueprint Medicines for approximately $9.5 billion, marking a significant move to broaden its portfolio of rare disease treatments and enhance its early-stage pipeline in immunology. At the heart of this acquisition lies Avapritinib (Ayvakit/Ayvakyt), the pioneering specific drug for systemic mastocytosis, already launched in China and incorporated into diagnostic and treatment guidelines. Furthermore, the deal encompasses Blueprint Medicines' next-generation drug elenestinib and the KIT inhibitor BLU-808, which is currently in the research and development phase.

In recent years, Sanofi has underscored its commitment to continuous expansion in the pharmaceutical industry, particularly in the domains of rare diseases and immunology, through a series of strategic acquisitions. This latest acquisition underscores Sanofi's ambition to further solidify its position as a global leader in immunology.